Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases
Heart Podcast
00:00
Cardiovascular Benefits of SGLT2 Inhibitors
Exploring the unexpected cardiovascular advantages of SGLT2 inhibitors, this chapter details the significant reduction in heart failure risk and mortality rates observed in patients with type 2 diabetes. Highlighting the outcomes from trials like DAPA HF and Empareg Used Trials, the discussion extends to the potential use of these medications in patients with coronary artery disease and even those at risk of atrial fibrillation and valvular heart disease.
Transcript
Play full episode
